| Literature DB >> 32269156 |
Rafael Wesley Bastos1, Clara Valero1, Lilian Pereira Silva1, Taylor Schoen2,3, Milton Drott2, Verônica Brauer4, Rafael Silva-Rocha4, Abigail Lind5, Jacob L Steenwyk6, Antonis Rokas5,6, Fernando Rodrigues7,8, Agustin Resendiz-Sharpe9, Katrien Lagrou9,10, Marina Marcet-Houben11,12,13, Toni Gabaldón11,12,13,14, Erin McDonnell15, Ian Reid15, Adrian Tsang15, Berl R Oakley16, Flávio Vieira Loures17, Fausto Almeida4, Anna Huttenlocher2,3, Nancy P Keller2, Laure Nicolas Annick Ries18, Gustavo H Goldman19.
Abstract
Aspergillus nidulans is an opportunistic fungal pathogen in patients with immunodeficiency, and virulence of A. nidulans isolates has mainly been studied in the context of chronic granulomatous disease (CGD), with characterization of clinical isolates obtained from non-CGD patients remaining elusive. This study therefore carried out a detailed biological characterization of two A. nidulans clinical isolates (CIs), obtained from a patient with breast carcinoma and pneumonia and from a patient with cystic fibrosis that underwent lung transplantation, and compared them to the reference, nonclinical FGSC A4 strain. Both CIs presented increased growth in comparison to that of the reference strain in the presence of physiologically relevant carbon sources. Metabolomic analyses showed that the three strains are metabolically very different from each other in these carbon sources. Furthermore, the CIs were highly susceptible to cell wall-perturbing agents but not to other physiologically relevant stresses. Genome analyses identified several frameshift variants in genes encoding cell wall integrity (CWI) signaling components. Significant differences in CWI signaling were confirmed by Western blotting among the three strains. In vivo virulence studies using several different models revealed that strain MO80069 had significantly higher virulence in hosts with impaired neutrophil function than the other strains. In summary, this study presents detailed biological characterization of two A. nidulans sensu stricto clinical isolates. Just as in Aspergillus fumigatus, strain heterogeneity exists in A. nidulans clinical strains that can define virulence traits. Further studies are required to fully characterize A. nidulans strain-specific virulence traits and pathogenicity.IMPORTANCE Immunocompromised patients are susceptible to infections with opportunistic filamentous fungi from the genus Aspergillus Although A. fumigatus is the main etiological agent of Aspergillus species-related infections, other species, such as A. nidulans, are prevalent in a condition-specific manner. A. nidulans is a predominant infective agent in patients suffering from chronic granulomatous disease (CGD). A. nidulans isolates have mainly been studied in the context of CGD although infection with A. nidulans also occurs in non-CGD patients. This study carried out a detailed biological characterization of two non-CGD A. nidulans clinical isolates and compared the results to those with a reference strain. Phenotypic, metabolomic, and genomic analyses highlight fundamental differences in carbon source utilization, stress responses, and maintenance of cell wall integrity among the strains. One clinical strain had increased virulence in models with impaired neutrophil function. Just as in A. fumigatus, strain heterogeneity exists in A. nidulans clinical strains that can define virulence traits.Entities:
Keywords: Aspergillus nidulanszzm321990; clinical isolates; genome sequencing; metabolomics
Mesh:
Substances:
Year: 2020 PMID: 32269156 PMCID: PMC7142298 DOI: 10.1128/mSphere.00153-20
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
FIG 1The A. nidulans clinical isolates exhibit improved growth in the presence of alternative carbon and lipid sources. Strains were grown in liquid MM supplemented with glucose, acetate, ethanol, mucin, Tween 20 and 80, olive oil, and Casamino Acids at 37°C for 48 h (glucose) or 72 h (others) before fungal biomass was freeze-dried and weighed. Standard deviations were determined from biological triplicates in a one-way ANOVA with Tukey’s posttest comparing growth of the clinical isolates to that of the FGSC A4 reference strain (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
Number and percentage of identified metabolite quantities that were significantly different in the A. nidulans clinical isolates
| Carbon source ( | No. (%) of differentially produced metabolites | |
|---|---|---|
| MO80069 vs FGSC A4 | SP-2605-48 vs FGSC A4 | |
| Glucose (40) | 18 (45) | 15 (38) |
| Ethanol (40) | 22 (55) | 23 (58) |
| Acetate (44) | 23 (52) | 30 (68) |
| Mucin (44) | 24 (55) | 14 (32) |
Metabolite quantities in A. nidulans clinical isolates were compared to those of the reference strain (P < 0.05). Strains were grown in the presence of the indicated carbon source for 16 h.
n, number of metabolites tested.
FIG 2The A. nidulans clinical isolates are metabolically different from the reference strain in the presence of different carbon sources. (A to D) Heat maps depicting log fold changes of identified metabolite quantities that were significantly (P < 0.05) different in the A. nidulans clinical isolates MO80069 and SP-2605-48 compared to levels in the FGSC A4 reference strain (gray squares depict metabolite quantities that were not detected as significantly different in one of the clinical isolates).
Significant metabolic pathway enrichments
| Carbon source | Enriched pathways in: | |
|---|---|---|
| MO80069 | SP-2605-48 | |
| Glucose | Aminoacyl-tRNA biosynthesis, arginine | Aminoacyl-tRNA biosynthesis, arginine |
| Acetate | Aminoacyl-tRNA biosynthesis; alanine, | Aminoacyl-tRNA biosynthesis, beta- |
| Ethanol | Aminoacyl-tRNA biosynthesis, arginine | Aminoacyl-tRNA biosynthesis, arginine |
FIG 3The A. nidulans clinical isolates are more sensitive to the cell wall-perturbing agents. (A to C) Strains were grown from 105 spores on glucose minimal medium supplemented with increasing concentrations of caspofungin, Congo red, and calcofluor white for 5 days at 37°C. Standard deviations represent biological triplicates in a two-way ANOVA test, comparing growth of the clinical isolates to growth of the FGSC A4 reference strain (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
MICs of voriconazole, posaconazole, and amphotericin B for the A. nidulans clinical isolates MO80069 and SP-2605-48 and the FGSC A4 reference strain
| Strain | MIC (μg/ml) | ||
|---|---|---|---|
| Voriconazole | Posaconazole | Amphotericin B | |
| FGSC A4 | 0.25 | 1.0 | 2.0 |
| MO80069 | 0.25 | 1.0 | 2.0 |
| SP260548 | 0.25 | 1.0 | 2.0 |
Cleistothecium formation and density and ascospore viability resulting from diverse A. nidulans self- and outcrosses
| Temp (°C) | Cross | Cleistothecium | Cleistothecium density (no. | Ascospore viability (%) |
|---|---|---|---|---|
| 30 | A4 × A4 | Yes | 15.0 ± 0.81 | 91.83 ± 3.53 |
| MO × MO | Yes | 7.0 ± 1.35 | 92.83 ± 3.96 | |
| SP × SP | Yes | 0.25 ± 0.25 | 89.83 ± 3.51 | |
| MO × R21 | Yes | 1.25 ± 0.25 | 94.83 ± 3.85 | |
| SP × R21 | No | |||
| 37 | A4 × A4 | Yes | 9.75 ± 1.43 | 90.67 ± 3.62 |
| MO × MO | Yes | 5.25 ± 1.31 | 92.5 ± 2.76 | |
| SP × SP | No | |||
| MO × R21 | Yes | 5.0 ± 0.40 | 92.5 ± 1.28 | |
| SP × R21 | No |
A4, FGSC A4 reference strain; MO, MO80069 clinical isolate; SP, SP-2605-48 clinical isolate; R21, R21XR135, paba-deficient strain.
Strains used in this study
| Strain | Genotype | Source | Reference |
|---|---|---|---|
| FGSC-A4 | Glasgow wild type ( | Soil | |
| MO80069 | Wild type, clinical | Bronchoalveolar lavage | This study |
| SP-2605-48 | Wild type, clinical | Patient with cystic fibrosis | This study |
| R21XR135 | NA | This study | |
| MO80069 | This study | This study | |
| SP-2605-48 | This study | This study | |
| NA |
NA, not applicable.
Type and number of SNPs and long indels detected between the genomes of the A. nidulans clinical isolates MO80069 and SP-2605-48 and compared to the FGSC A4 reference genome
| Mutation type | No. of mutations | ||
|---|---|---|---|
| MO80069 vs FGSC A4 | SP-2605-48 vs FGSC A4 | SP-2605-48 vs MO80069 | |
| SNPs | |||
| Stop codon gain/loss | 149 | 110 | 170 |
| Frameshift | 352 | 355 | 256 |
| Missense | 6,271 | 5,896 | 6,288 |
| Synonymous | 6,184 | 6,038 | 6,122 |
| Total | 12,956 | 12,399 | 12,836 |
| Indels | |||
| Insertions | 234 | 308 | 222 |
| Deletion | 114 | 138 | 207 |
| Total | 348 | 446 | 375 |
FIG 4Diagram depicting the location of all detected nonsynonymous single nucleotide polymorphisms (SNPs) on the 8 chromosomes (Chr I to Chr VIII) of the A. nidulans clinical isolates SP-2605-48 and MO80069 in comparison to the FGSC A4 reference genome.
FIG 5Diagram depicting the location of all detected small deletions on the 8 chromosomes (Chr I to Chr VIII) of the A. nidulans clinical isolates SP-2605-48 and MO80069 in comparison to the FGSC A4 reference genome. Also shown are the locations of putative transposons in the A. nidulans reference genome.
FIG 6MpkA is not phosphorylated in the A. nidulans clinical isolates MO80069 and SP-2605-48 in the presence of NaCl-induced cell wall stress in contrast to MpkA levels in the FGSC A4 reference strain. Strains were grown from 1 × 107 spores in complete medium for 16 h (control, 0 min) at 37°C before 0.5 M NaCl was added for 10 min (10′) and 30 min (30′). Total cellular protein was extracted, and Western blotting was carried out probing for phosphorylated MpkA. Signals were normalized by the amount of total MpkA present in the protein extracts, and cellular extracts from the ΔmpkA strain were used as a negative control.
FIG 7The A. nidulans clinical isolates MO80069 and SP-2605-48 do not present increased survival in the presence of macrophages and neutrophils. (A) Percentage of phagocytized conidia by murine wild-type and gp91phox knockout macrophages. Macrophages were incubated for 1.5 h with conidia from the respective strains before phagocytized conidia were counted. (B) CFU counts as a measure of conidium viability after passage through wild-type (wt) and gp91phox knockout macrophages. Macrophages were incubated with the respective conidia for 1.5 h before they were lysed, and contents were plated on complete medium. (C) Percentage of viable hyphal germlings after incubation for 16 h with neutrophils from healthy human donors. Strain viability was calculated relative to incubation without PMN cells, which was set at 100% for each sample. Standard deviations represent biological triplicates in a one-way ANOVA test with Tukey’s posttest (*, P < 0.05; **, P < 0.01, for results for the clinical isolates compared to those for FGSC A4; #, P < 0.05, for a comparison of results for the two types of macrophages in the same strain).
FIG 8A. nidulans strain-specific virulence depends on the host immune status. The virulence of the A. nidulans clinical isolates MO80069 and SP-260548 was tested in murine (A, C, and E) and zebrafish (B, D, and F) models of pulmonary and invasive aspergillosis. Animals were manipulated in order to give rise to either immunocompetent (A and B), CGD (chronic granulomatous disease) (C and D), or neutropenic (E)/neutrophilic (F) models. Shown are survival curves for each immunosuppression condition and animal model. No difference in virulence levels was detected for all strains in both immunocompetent and CGD mice. Strain MO80069 was significantly more virulent in neutropenic mice and neutrophilic zebrafish. **, P < 0.01; ****, P < 0.0001 for a comparison of the values for the clinical isolates to those of the FGSC A4 reference strain in a two-way ANOVA test with Tukey’s posttest.